Author

E. Barreto-Duran

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

A. Szczepanski· 2 shared K. Pyrc· 2 shared A. Czarna· 1 shared A. Dabrowska· 1 shared A. Matsuda· 1 shared A. Milewska· 1 shared A. Mourao· 1 shared B. Blomberg· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

A. Szczepanski

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Acriflavine, a clinically aproved drug, inhibits SARS-CoV-2 and other betacoronaviruses

V. Napolitano, A. Dabrowska, K. Schorpp, A. Mourao, E. Barreto-Duran, M. Benedyk, P. Botwina, S. Brandner, M. Bostock, Y. Chykunova, A. Czarna, G. Dubin, T. Frohlich, M. Hoelscher, M. Jedrysik, , K. Pyrc

This study identifies acriflavine as a potent inhibitor of SARS-CoV-2 and other betacoronaviruses, effective in cellular models, in vivo, and ex vivo.

bioRxiv · Mar 20, 2021Microbiology

HTCC as a highly effective polymeric inhibitor of SARS-CoV-2 and MERS-CoV

A. Milewska, Y. Chi, A. Szczepanski, E. Barreto-Duran, K. Liu, D. Liu, X. Guo, Y. Ge, J. Li, L. Cui, M. Ochman, M. Urlik, S. Rodziewicz-Motowidlo, F. Zhu, K. Szczubialka, , K. Pyrc

This paper evaluates HTCC as a potential inhibitor for SARS-CoV-2 and MERS-CoV, highlighting its antiviral activity against highly pathogenic coronaviruses.

bioRxiv · Mar 29, 2020 · PreprintMicrobiology